德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06996 德琪医药-B

交易中 03-16 10:45:07

4.010

-0.140

-3.37%

最高4.200	最低3.940	成交量124.20万
今开4.130	昨收4.150	日振幅6.27%
总市值27.23亿	流通市值27.23亿	总股本6.79亿
成交额499.45万	换手率0.18%	流通股本6.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":4.01,"timestamp":1773629090499,"preClose":4.15,"halted":0,"volume":1242000,"delay":0,"changeRate":-0.03373493975903628,"floatShares":679000000,"shares":679000000,"eps":-0.5835665120341887,"marketStatus":"交易中","change":-0.14,"latestTime":"03-16 10:45:07","open":4.13,"high":4.2,"low":3.94,"amount":4994530,"amplitude":0.062651,"askPrice":4.02,"askSize":6500,"bidPrice":4,"bidSize":68500,"shortable":3,"etf":0,"ttmEps":-0.41849228637847224,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1773633600000},"marketStatusCode":2,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":4.15,"openAndCloseTimeList":[[1773624600000,1773633600000],[1773637200000,1773648000000]],"volumeRatio":0.611977,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996","defaultTab":"news","newsList":[{"id":"2618935416","title":"每日卖空追踪 | 德琪医药-B 03月10日卖空量成交26.75万股，卖空比例为1.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618935416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618935416?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131438,"startTime":"0","endTime":"0","summary":"德琪医药-B北京时间03月10日，涨11.5%，卖空量成交26.75万股，较上一交易日减少48.11%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163550a45df9f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163550a45df9f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","06996","BK1191","BK1574"],"gpt_icon":0},{"id":"2618497935","title":"德琪医药-B盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618497935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618497935?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:41","pubTimestamp":1773106901,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时41分，德琪医药-B股票出现异动，股价快速上涨5.00%。截至发稿，该股报4.200港元/股，成交量55.05万股，换手率0.08%，振幅4.50%。资金方面，该股资金流入115.616万港元，流出105.306万港元。德琪医药-B股票所在的药品行业中，整体涨幅为0.65%。德琪医药-B公司简介：德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要在亚太地区开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094141a45ceb35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094141a45ceb35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1191","BK1574","06996"],"gpt_icon":0},{"id":"2618260871","title":"德琪医药-B(06996.HK)拟3月20日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618260871","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618260871?lang=zh_cn&edition=full","pubTime":"2026-03-10 07:07","pubTimestamp":1773097622,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨德琪医药-B(06996.HK)宣布，本公司将于2026年3月20日(星期五)举行董事会会议，藉以(其中包括)考虑并批准本公司及其附属公司截至2025年12月31日止年度业绩及其发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260310/32055270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1191","06996","BK1583"],"gpt_icon":0},{"id":"2618628681","title":"China International Capital Corporation Limited增持德琪医药(06996)62.7万股 每股作价约3.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628681","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618628681?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:53","pubTimestamp":1773053581,"startTime":"0","endTime":"0","summary":"据香港联交所最新数据显示，3月4日，China International Capital Corporation Limited增持德琪医药(06996)62.7万股，每股作价3.0616港元，总金额约为191.96万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260309/20260309185332_48275.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260309/20260309185332_48275.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1583","BK1191","06996"],"gpt_icon":0},{"id":"2618117935","title":"近期交易合作|正大天晴小分子靶向药授权赛诺菲，德琪医药双抗授权优时比","url":"https://stock-news.laohu8.com/highlight/detail?id=2618117935","media":"药菓","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618117935?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:00","pubTimestamp":1773050411,"startTime":"0","endTime":"0","summary":"2026近期合作 & 交易事件01 睿跃生物被Gyre收购02 黑石押注梯瓦开发TL1A单抗03 正大天晴新药授权赛诺菲04 德琪医药CD3/CD19双抗授权给优时比05 施维雅25亿美元收购Day One01睿跃生物被Gyre收购2026年3月2日，美国Gyre Therapeutics宣布将以全股票交易方式收购睿跃生物，交易估值约3亿美元。03正大天晴新药授权赛诺菲3月4日，中国生物制药子公司正大天晴已与赛诺菲就JAK/ROCK抑制剂罗伐昔替尼在全球的开发、生产及商业化订立独家授权协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091807369545f3b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091807369545f3b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1583","BK1574","06996"],"gpt_icon":0},{"id":"2617655039","title":"德琪医药-B获中金公司增持62.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617655039","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617655039?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:09","pubTimestamp":1772806198,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨根据联交所最新权益披露资料显示，2026年3月4日，德琪医药-B(06996.HK)获China International Capital Corporation Limited在场内以每股均价3.0616港元增持好仓62.7万股，涉资约192万港元。增持后，China International Capital Corporation Limited最新持好仓数目为4076.35万股，持好仓比例由5.90%上升至6.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306221011a6ab302a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306221011a6ab302a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","06996","03908","SG9999002828.SGD","BK1147","BK1501","BK1191","BK1564","BK1583","BK1516","BK1574","LU1023057109.AUD","LU0359201885.HKD","LU0359201612.USD"],"gpt_icon":0},{"id":"2617387416","title":"每日卖空追踪 | 德琪医药-B 03月06日卖空量成交28.35万股，卖空比例为5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617387416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617387416?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:30","pubTimestamp":1772785838,"startTime":"0","endTime":"0","summary":"德琪医药-B北京时间03月06日，涨1.3%，卖空量成交28.35万股，较上一交易日减少55.7%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163559a6aa404e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163559a6aa404e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","BK1583","06996"],"gpt_icon":0},{"id":"2617638749","title":"一周医药速览（02.02-02.06）","url":"https://stock-news.laohu8.com/highlight/detail?id=2617638749","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617638749?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:45","pubTimestamp":1772783158,"startTime":"0","endTime":"0","summary":"京东健康：2025年净利润增长29.1%至53.75亿元，全年新药首发超100款近日，京东健康发布截至2025年12月31日止年度的年度业绩公告。截至2025年底，公司自营药房门店已超过300家。德琪医药将获得8000万美元的首付款及近期里程碑付款，其中包括6000万美元的首付款和满足若干条件后额外支付的2000万美元里程碑付款。公告显示，整体收入为5.49亿美元，较2024年下降13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306155002a4532b1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306155002a4532b1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","06996","BK1583","BK1191","BK1574","01177","09939"],"gpt_icon":0},{"id":"2617503918","title":"【券商聚焦】交银国际维持德琪医药(06996)买入评级 看好其差异化管线资产的潜在价值和BD出海机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2617503918","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617503918?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:03","pubTimestamp":1772759029,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，德琪医药-B 将授予优时比CD19/CD3双特异性T细胞连接抗体ATG-201的全球独家权益。根据协议条款，德琪医药将获得总计8,000万美元近期付款，包括6,000万美元首付款以及2,000万美元近期里程碑付款，并有望在未来获得最高超过11亿美元的里程碑付款及基于未来净销售额的分级特许权使用费。该机构看好公司CLDN18.2 ADC、TCE、口服CD73等差异化管线资产的潜在价值和BD出海机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"gpt_icon":0},{"id":"1126598197","title":"德琪医药-B（06996）2月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1126598197","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126598197?lang=zh_cn&edition=full","pubTime":"2026-03-05 12:26","pubTimestamp":1772684764,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年3月5日披露截至2026年2月28日止的股份变动月报表。本期内公司股本未发生任何增发、回购或注销，整体规模保持稳定。截至2026年2月底，公司法定股本为2,000,000,000股，面值每股0.0001美元，合计200,000美元，与上月持平；已发行普通股数量维持在679,244,132股，另有202,500股库存股份，总股本合计679,446,632股，报告期内无变动。公司同时确认已符合香港联交所对于上市公司公众持股比例的相关要求。本次公告由主席梅建明博士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"gpt_icon":0},{"id":"2617595428","title":"港股异动 | 德琪医药-B(06996)再涨超11% 与优时比达成近12亿美元授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2617595428","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617595428?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:31","pubTimestamp":1772677897,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B(06996)再涨超11%，该股昨日收涨近10%。截至发稿，涨11.71%，报3.53港元，成交额715.17万港元。消息面上，德琪医药日前与优时比宣布，双方已签署协议，德琪医药将授予优时比在全球范围内推进CD19/CD3双特异性T细胞连接抗体ATG-201的开发、生产及商业化的独家权益，并包括与ATG-201相关的生产技术授权。德琪医药将获得总计8000万美元（包括6000万美元首付款以及额外2000万美元近期里程碑付款），并有望在未来获得最高超过11亿美元的里程碑付款及基于未来净销售额的分级特许权使用费。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","06996","BK1583","BK4585","BK1191","VT","VXUS","BK1574"],"gpt_icon":0},{"id":"2617591554","title":"超11亿美元！国产CD3/CD19双抗达成海外授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2617591554","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617591554?lang=zh_cn&edition=full","pubTime":"2026-03-05 08:59","pubTimestamp":1772672382,"startTime":"0","endTime":"0","summary":"3月4日，德琪医药发布公告宣布，与优时比达成授权协议。根据授权协议，德琪医药授予优时比进一步开发、生产及商业化ATG-201，并使用相关生产技术的全球独家授权。ATG-201是一款在研的CD19/CD3双特异性T细胞衔接器，专为治疗由B细胞介导的自身免疫性疾病而设计与开发。德琪医药计划于2026年第一季度在中国及澳大利亚提交ATG-201的临床试验申请，并将在上述两个地区完成首次人体（一期）临床研究后把ATG-201的后续临床及其他相关开发工作移交予优时比。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305091337a44d4133&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305091337a44d4133&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","BK1583","06996"],"gpt_icon":0},{"id":"2617567493","title":"德琪医药新药授权给优时比；司美格鲁肽治疗MASH拟纳入优先审评｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2617567493","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617567493?lang=zh_cn&edition=full","pubTime":"2026-03-05 07:09","pubTimestamp":1772665768,"startTime":"0","endTime":"0","summary":"丨2026年3月5日星期四丨NO.1德琪医药CD19/CD3双抗新药授权给优时比德琪医药与优时比（UCB）联合宣布，双方已签署协议，德琪医药将授予优时比在全球范围内推进CD19/CD3双特异性T细胞连接抗体ATG-201的开发、生产及商业化的独家权益，并包括与ATG-201相关的生产技术授权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603053662203576.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053662203576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1191","BK1161","BK1515","BK1574","BK1583","06996","159938"],"gpt_icon":0},{"id":"2617591585","title":"每日卖空追踪 | 德琪医药-B 03月04日卖空量成交51.1万股，卖空比例为4.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617591585","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617591585?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613038,"startTime":"0","endTime":"0","summary":"德琪医药-B北京时间03月04日，涨9.72%，卖空量成交51.1万股，较上一交易日增加86.16%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163613a44a7115&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163613a44a7115&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1191","06996"],"gpt_icon":0},{"id":"2616309161","title":"港股异动 | 德琪医药-B(06996)高开逾11% CD19/CD3双抗授权优时比 潜在交易额逾11.8亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616309161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616309161?lang=zh_cn&edition=full","pubTime":"2026-03-04 09:26","pubTimestamp":1772587565,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B高开逾11%，截至发稿，涨11.11%，报3.2港元，成交额65.92万港元。消息面上，德琪医药与优时比今日联合宣布，双方已签署协议，德琪医药将授予优时比在全球范围内推进CD19/CD3双特异性T细胞连接抗体ATG-201的开发、生产及商业化的独家权益，并包括与ATG-201相关的生产技术授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","06996","BK1191","BK4588","BK4585","BK1583","VT","BK1574"],"gpt_icon":0},{"id":"2616377953","title":"德琪医药-B(06996)与优时比就ATG-201达成全球独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2616377953","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616377953?lang=zh_cn&edition=full","pubTime":"2026-03-04 06:13","pubTimestamp":1772576004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 公布，于2026年3月3日，公司全资附属公司Antengene Biologics Limited及德琪(杭州)生物有限公司与优时比达成授权协议。根据授权协议，许可方将授予被许可方进一步开发、生产及商业化ATG-201，并使用相关生产技术的全球独家授权。被许可方在全球约40个国家拥有超过9,000名员工，并于2025年录得77亿欧元的收入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B(06996)与优时比就ATG-201达成全球独家授权协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","BK1574","06996"],"gpt_icon":0},{"id":"1183715006","title":"德琪医药-B有望获得最高11亿美元未来成功导向开发及商业化里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1183715006","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183715006?lang=zh_cn&edition=full","pubTime":"2026-03-04 06:10","pubTimestamp":1772575823,"startTime":"0","endTime":"0","summary":"德琪医药-B（Antengene Corp）宣布，其相关单位有资格获得基于未来成功条件的开发及商业化里程碑付款，总额最高可达11亿美元。该付款安排与特定研发成果及市场表现挂钩，凸显了公司创新管线的商业潜力。\n此项里程碑付款机制旨在激励关键项目的持续推进，涵盖从临床开发到商业上市的全周期。成功达成预设目标后，资金将分阶段发放，为德琪医药的长期发展提供财务支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1191","06996"],"gpt_icon":0},{"id":"1192296604","title":"德琪医药与优时比达成全球授权协议 共同开发自身免疫疾病双特异性T细胞衔接抗体ATGC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=1192296604","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192296604?lang=zh_cn&edition=full","pubTime":"2026-03-04 06:01","pubTimestamp":1772575282,"startTime":"0","endTime":"0","summary":"德琪医药有限公司宣布与比利时生物制药公司优时比签署全球独家授权协议，双方将共同开发创新药物ATGC-201。该药物是一款靶向CD19/CD3的双特异性T细胞衔接抗体，主要应用于自身免疫性疾病的治疗领域。根据协议条款，德琪医药将获得预付款、研发里程碑付款及商业化里程碑付款，总额有望达到数亿美元。此次合作将整合德琪医药在抗体药物研发领域的技术优势与优时比在全球自身免疫疾病市场的商业化经验，加速推进ATGC-201的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","06996","BK1574"],"gpt_icon":0},{"id":"2616379643","title":"每日卖空追踪 | 德琪医药-B 03月02日卖空量成交6.55万股，卖空比例为4.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616379643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616379643?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:30","pubTimestamp":1772440241,"startTime":"0","endTime":"0","summary":"德琪医药-B北京时间03月02日，跌5.2%，卖空量成交6.55万股，较上一交易日减少83.1%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163646a730ca3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163646a730ca3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1191","BK1574","06996"],"gpt_icon":0},{"id":"2616337994","title":"德琪医药-B03月02日遭主力抛售20.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337994","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616337994?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:16","pubTimestamp":1772439363,"startTime":"0","endTime":"0","summary":"03月02日, 德琪医药-B股价跌5.20%，报收3.10元，成交金额441.1万元，换手率0.21%，振幅7.03%，量比0.40。德琪医药-B今日主力资金净流出20.1万元，连续6日净流出，上一交易日主力净流出124.3万元。该股近5个交易日下跌14.25%，主力资金累计净流出853.2万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出1063.6万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302162349a4414191&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302162349a4414191&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","06996","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":0.0614},{"period":"1month","weight":0.1891},{"period":"3month","weight":-0.0568},{"period":"6month","weight":-0.422},{"period":"1year","weight":0.3742},{"period":"ytd","weight":0.095}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.0197},{"period":"6month","weight":-0.035},{"period":"1year","weight":0.0854},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.063895},{"month":4,"riseRate":0.4,"avgChangeRate":-0.055669},{"month":5,"riseRate":0.6,"avgChangeRate":0.040777},{"month":6,"riseRate":0.2,"avgChangeRate":-0.111296},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000904},{"month":8,"riseRate":0.4,"avgChangeRate":-0.030428},{"month":9,"riseRate":0.4,"avgChangeRate":-0.020432},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"德琪医药-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}